Pay in 4 interest-free payments of $7.33 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
GLP-1 Receptor Agonist Market Report 2026 Global Outlook By Drug Class (Exenatide, Liraglutide, Dulaglutide, Lixisenatide, Other Drugs), By Route Of Administration (Parenteral, Oral), By End Users (Hospitals, Surgical Clinics, Other Users) Market Size, Trends, Strategies, and Forecast to 2035 GLP-1 Receptor Agonist Market Overview GLP-1 Receptor Agonist market size has reached to $14.09 billion in 2025 Expected to grow to $18.32 billion in 2030 at a compound annual growth rate (CAGR) of 5.4% Growth Driver: Surging Diabetes Cases Fuel Growth In Glp-1 Receptor Agonist Market Market Trend: Sustained-Release Glp-1 Receptor Agonists Are Gaining Popularity North America was the largest region in 2025 and Asia-Pacific is the fastest growing region
50 Reduced HRQoL in HF is multifactorial and related to frequent readmissions and symptom burden, exercise intolerance, emotional distress, loss of independence and social limitations
the first crystal structure of human GGT was solved in 2013 (West et al., 2013)
To overcome the problem, prodrugs activated only after oral absorption were developed
doi: 10.1080/02713683.2022.2103153 189 KhanRSDineKBaumanBLorentsenMLinLBrownHet al
Observational studies and clinical practice suggest that these patients would benefit more from an LSG or RYBG intervention than LAGB, although there are currently no published randomised clinical trials showing the superiority of one procedure in terms of long-term glycaemic control and remission of T2DM [10, 34]
US$ 28.40
US$ 23.65
US$ 20.76
